<?xml version="1.0" encoding="UTF-8"?>
<p>Preoperative adjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU) is currently used with beneficial effects to treat localized advanced ESCC in Japan.
 <sup>[
  <xref rid="R2" ref-type="bibr">2</xref>,
  <xref rid="R3" ref-type="bibr">3</xref>,
  <xref rid="R10" ref-type="bibr">10</xref>]
 </sup> We previously reported that TRPV2 appeared to play a role in maintaining CSCs, and that tranilast, its inhibitor, may enhance the effects of conventional preoperative adjuvant chemotherapy against ESCC.
 <sup>[
  <xref rid="R7" ref-type="bibr">7</xref>]
 </sup> The present study is being performed to confirm the safety and efficacy of the additional use of tranilast with 5-FU/CDDP and to develop a novel therapeutic strategy for patients with advanced ESCC.
</p>
